CUTIA-B total transfer market value is HKD 91.5584 million, accounting for 7.07%, with 25.7205 million shares transferre…
I'm LongbridgeAI, I can summarize articles.According to the latest information from the Hong Kong Stock Exchange, on June 4th, CUTIA-B experienced a position change, with a total transfer market value of HKD 91.5584 million, accounting for 7.07%. The company's shareholders transferred 25.7061 million shares to Citibank and transferred out 25.7205 million shares from Morgan Stanley Hong Kong Securities. CUTIA-B announced that the group's CU-30101 (topical lidocaine-bupivacaine cream) has obtained marketing authorization from the National Medical Products Administration (NMPA) of the People's Republic of China. CU-30101 is a topical lidocaine-bupivacaine composite cream used for epidermal anesthesia procedures. Due to its unique pharmacokinetic properties, the combination formula of lidocaine and bupivacaine in CU-30101 can produce rapid and long-lasting anesthetic effects. Lidocaine diffuses faster and has a wider diffusion range than bupivacaine, while bupivacaine is a long-acting amino acid ester local anesthetic that is more lipophilic than lidocaine and can concentrate in the epidermal stratum corneum. In addition, the topical cream formulation also limits the systemic absorption of the anesthetic components, thus providing good safety
According to the latest information from the Hong Kong Stock Exchange, on June 4th, CUTIA-B (02487) experienced a position change, with a total transfer market value of HKD 91.5584 million, accounting for 7.07%. The company's shareholders transferred 25.7061 million shares to Citibank and withdrew 25.7205 million shares from Morgan Stanley Hong Kong Securities.
CUTIA-B (02487) announced that the group's CU-30101 (topical lidocaine-bupivacaine cream) has obtained marketing authorization from the National Medical Products Administration of the People's Republic of China.
CU-30101 is a topical lidocaine-bupivacaine composite cream used for epidermal anesthesia procedures. Due to the unique pharmacokinetic properties of its components, the combination formula of lidocaine and bupivacaine in CU-30101 can produce rapid and lasting anesthetic effects. Lidocaine diffuses faster and has a wider diffusion range than bupivacaine, while bupivacaine is a long-acting amino acid ester local anesthetic that is more lipophilic than lidocaine and can concentrate in the epidermal stratum corneum. In addition, the topical cream formulation also limits the systemic absorption of the anesthetic components, thus providing good safety